tiprankstipranks
Trending News
More News >

AbCellera receives NOL from Health Canada for ABCL635 clinical trial application

AbCellera (ABCL) announced it has received a No Objection Letter from Health Canada authorizing its clinical trial application for ABCL635, an investigational antibody antagonist targeting neurokinin 3 receptor that is being developed for the non-hormonal treatment of moderate-to-severe vasomotor symptoms, commonly known as hot flashes, associated with menopause. The Phase 1 study is anticipated to begin in Q3 and will evaluate ABCL635’s safety, pharmacokinetics, and pharmacodynamics in healthy participants and postmenopausal women with moderate-to-severe VMS.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1